CAR-T cells targeting GPRC5D for relapsed multiple myeloma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of cell therapy (CAR-T cells) that targets a protein called GPRC5D on myeloma cells. It is for people with multiple myeloma that has come back or not responded to several prior treatments, including immunomodulators, proteasome inhibitors, and anti-CD38 antibodies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that has come back or not responded to at least 3 different treatments (including an immunomodulator, a proteasome inhibitor, and an anti-CD38 antibody).
- Your myeloma cells have a marker called GPRC5D on their surface (more than 20% of cells).
- You have a measurable sign of myeloma, such as a certain level of M protein in your blood or urine, or a certain percentage of myeloma cells in your bone marrow.
- You are expected to live at least 12 more weeks, and you are generally well enough to be up and about (ECOG score 0, 1, or 2).
- You have not had treatment that targets GPRC5D before, and you do not have active infections, hepatitis B/C, HIV, or a history of certain transplants.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a CAR T-cell treatment made to find a specific marker called GPRC5D on myeloma (or plasma cell leukemia) cells. It may help people whose disease has returned or hasn’t responded to several prior treatments.
This trial tests a new type of CAR-T cell therapy that targets a protein called GPRC5D on multiple myeloma cells. It is for people whose myeloma has not responded to or has returned after at least three prior treatments, and aims to see if this targeted approach can help control the disease.
This trial tests a new CAR-T cell treatment that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is for patients whose multiple myeloma has come back or stopped responding to treatment and has spread outside the bone marrow (extramedullary disease). The goal is to see if this dual-target approach can attack the cancer more effectively.
This study tests a new type of cell therapy called CAR-T, which uses your own immune cells to fight the cancer. It is for people with multiple myeloma that has come back or not responded to at least three previous treatments.
This trial tests a new type of cell therapy (CAR-T) that targets two proteins on myeloma cells: GPRC5D and CD19. It is for people whose myeloma has come back or stopped responding to at least 3 prior treatments. The goal is to see if this treatment is safe and helps control the disease.
This Phase 1 trial tests a CAR T-cell treatment made to target a protein called GPRC5D on myeloma cells. It may help patients whose multiple myeloma or plasma cell leukemia has come back or stopped responding to prior treatments.
Hear when a new Relapsed and/or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.